CIK 0001357874
- Non-accelerated filer
- Smaller reporting company
PRECISION BIOSCIENCES INC
Sign in to watch- Ticker
- DTIL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- May 21
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 919-314-5512
- Business address
- 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM, NC, 27701
- Open-market buys, last 90 days
- $29,501
- in 3 filings
- Open-market sales, last 90 days
- $27,505
- in 1 filing, $28K under 10b5-1 plans
Net +$1,996. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 39 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-05-14 | JANTZ DEREK Chief Scientific Officer | Sale | −9,673 | $9.17 | $89K | 4,052,279 |
| 2021-05-14 | JANTZ DEREK Chief Scientific Officer | Option exercise · Employee Stock Option (Right to Buy) | −21,514 | 0 | ||
| 2021-05-13 | KANE MATTHEW R. President and CEO | Option exercise | +21,514 | $0.04 | $861 | 2,023,272 |
| 2021-05-13 | KANE MATTHEW R. President and CEO | Sale | −9,675 | $8.96 | $87K | 2,013,597 |
| 2021-05-13 | KANE MATTHEW R. President and CEO | Option exercise · Employee Stock Option (Right to Buy) | −21,514 | 0 | ||
| 2021-05-13 | JANTZ DEREK Chief Scientific Officer | Option exercise | +21,514 | $0.04 | $861 | 4,050,111 |
| 2021-05-13 | JANTZ DEREK Chief Scientific Officer | Sale | −9,673 | $9.15 | $89K | 4,040,438 |
| 2021-05-13 | JANTZ DEREK Chief Scientific Officer | Option exercise · Employee Stock Option (Right to Buy) | −21,514 | 21,514 | ||
| 2021-05-12 | JANTZ DEREK Chief Scientific Officer | Option exercise | +21,514 | $0.04 | $861 | 4,038,273 |
| 2021-05-12 | JANTZ DEREK Chief Scientific Officer | Sale | −9,676 | $8.72 | $84K | 4,028,597 |
| 2021-05-12 | JANTZ DEREK Chief Scientific Officer | Option exercise · Employee Stock Option (Right to Buy) | −21,514 | 43,028 | ||
| 2021-05-10 | Sharp Shalini Director | Grant or award · Stock Option (Right to Buy) | +32,800 | 32,800 | ||
| 2021-05-10 | Schinazi Raymond F Director | Grant or award · Stock Option (Right to Buy) | +32,800 | 32,800 | ||
| 2021-05-10 | Germano Geno J Director | Grant or award · Stock Option (Right to Buy) | +32,800 | 32,800 | ||
| 2021-05-10 | Buehler Kevin Director | Grant or award · Stock Option (Right to Buy) | +32,800 | 32,800 | ||
| 2021-05-10 | KANE MATTHEW R. President and CEO | Option exercise | +21,514 | $0.04 | $861 | 2,011,504 |
| 2021-05-10 | KANE MATTHEW R. President and CEO | Sale | −9,746 | $8.25 | $80K | 2,001,758 |
| 2021-05-10 | KANE MATTHEW R. President and CEO | Option exercise · Employee Stock Option (Right to Buy) | −21,514 | 21,514 | ||
| 2021-05-07 | KANE MATTHEW R. President and CEO | Option exercise | +21,514 | $0.04 | $861 | 1,999,732 |
| 2021-05-07 | KANE MATTHEW R. President and CEO | Sale | −9,742 | $8.57 | $83K | 1,989,990 |
Page 20 of 23 · 456 trades